Who
Jeffrey S. Martini
Chief Scientific Officer
Company insider
Files Form 4 as: Chief Scientific Officer, Palvella Therapeutics.
In numbers
- Trades disclosed
- 5
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 13 Dec 2024
- Last trade
- 5 Feb 2026
- Last filed
- 9 Feb 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Feb 2026filed 9 Feb 2026 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —64,318 at $0.00 | filing |
| 5 Feb 2026filed 9 Feb 2026 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —64,318 at $0.00 | filing |
| 5 Feb 2025filed 10 Feb 2025 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,373 at $0.00 | filing |
| 5 Feb 2025filed 10 Feb 2025 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —123,559 at $0.00 | filing |
| 13 Dec 2024filed 17 Dec 2024 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —126,416 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.